Skip to main content
. 2023 Sep 26;31(1):178–191. doi: 10.1245/s10434-023-14308-3

Table 1.

Clinical and pathological characteristics of the training cohort and internal validation

Variables Total (n = 282) Training cohort (n = 141) Internal validation (n = 141) p-Value Statistic
Sex, n (%) 0.408 0.686
 Male 239 (84.8) 122 (86.5) 117 (83)
 Female 43 (15.2) 19 (13.5) 24 (17)
Age, n (%) 0.999 0
 < 65 years 194 (68.8) 97 (68.8) 97 (68.8)
 ≥ 65 years 88 (31.2) 44 (31.2) 44 (31.2)
Smoker, n (%) 0.201 1.632
 No 90 (31.9) 40 (28.4) 50 (35.5)
 Yes 192 (68.1) 101 (71.6) 91 (64.5)
Drinker, n (%) 0.059 3.572
 No 95 (33.7) 40 (28.4) 55 (39)
 Yes 187 (66.3) 101 (71.6) 86 (61)
Location, n (%) 0.468 1.52
 Up 39 (13.8) 18 (12.8) 21 (14.9)
 Middle 108 (38.3) 59 (41.8) 49 (34.8)
 Low 135 (47.9) 64 (45.4) 71 (50.4)
Differentiation, n (%) 0.495 1.408
 Well 24 (8.5) 14 (9.9) 10 (7.1)
 Middle 158 (56.0) 81 (57.4) 77 (54.6)
 Poor 100 (35.5) 46 (32.6) 54 (38.3)
Surgical margin, n (%) 0.122 Fisher
 Negative 278 (98.6) 137 (97.2) 141 (100)
 Positive 4 (1.4) 4 (2.8) 0 (0)
Nerve invasion, n (%) 0.424 0.638
 Negative 235 (83.3) 115 (81.6) 120 (85.1)
 Positive 47 (16.7) 26 (18.4) 21 (14.9)
Lymph, vascular invasion, n (%) 0.999 0
 Negative 258 (91.5) 129 (91.5) 129 (91.5)
 Positive 24 (8.5) 12 (8.5) 12 (8.5)
cT, n (%) 0.145 5.393
 2 19 (6.7) 9 (6.4) 10 (7.1)
 3 220 (78.0) 109 (77.3) 111 (78.7)
 4a 23 (8.2) 16 (11.3) 7 (5)
 4b 20 ( 7.1) 7 (5) 13 (9.2)
cN, n (%) 0.155 Fisher
 0 6 (2.1) 5 (3.5) 1 (0.7)
 1 100 (35.5) 55 (39) 45 (31.9)
 2 139 (49.3) 66 (46.8) 73 (51.8)
 3 37 (13.1) 15 (10.6) 22 (15.6)
ypT, n (%) 0.338 Fisher
 0 113 (40.1) 48 (34) 65 (46.1)
 1 36 (12.8) 19 (13.5) 17 (12.1)
 2 56 (19.9) 31 (22) 25 (17.7)
 3 74 (26.2) 41 (29.1) 33 (23.4)
 4 3 (1.1) 2 (1.4) 1 (0.7)
ypN, n (%) 0.969 Fisher
 1 188 (66.7) 93 (66) 95 (67.4)
 2 68 (24.1) 34 (24.1) 34 (24.1)
 3 24 (8.5) 13 (9.2) 11 (7.8)
 4 2 (0.7) 1 (0.7) 1 (0.7)
AJCC/TNM stage, n (%) 0.236 Fisher
 0 90 (31.9) 37 (26.2) 53 (37.6)
 I 63 (22.3) 36 (25.5) 27 (19.1)
 II 34 (12.1) 19 (13.5) 15 (10.6)
 III 91 (32.3) 46 (32.6) 45 (31.9)
 IV 4 (1.4) 3 (2.1) 1 (0.7)
pCR, n (%) 0.041 4.178
 Yes 90 (31.9) 37 (26.2) 53 (37.6)
 No 192 (68.1) 104 (73.8) 88 (62.4)
PT–TRG, n (%) 0.135 5.558
 0 112 (39.7) 48 (34) 64 (45.4)
 1 67 (23.8) 33 (23.4) 34 (24.1)
 2 83 (29.4) 47 (33.3) 36 (25.5)
 3 20 (7.1) 13 (9.2) 7 (5)
LN–TRG, n (%) 0.996 0.181
 0 170 (60.3) 85 (60.3) 85 (60.3)
 1 20 (7.1) 10 (7.1) 10 (7.1)
 2 17 (6.0) 9 (6.4) 8 (5.7)
 3 21 (7.4) 11 (7.8) 10 (7.1)
 4 54 (19.1) 26 (18.4) 28 (19.9)
Total carcinoma diameter (lymph node), mean ± SD 0.2 ± 0.4 0.2 ± 0.4 0.2 ± 0.3 0.432 0.619
Number of lymph nodes dissected 18.6 ± 8.3 17.6 ± 7.2 19.5 ± 9.2 0.055 3.703
WBC grade, n (%) 0.438 0.602
 0–2 196 (69.5) 101 (71.6) 95 (67.4)
 3–4 86 (30.5) 40 (28.4) 46 (32.6)
Hb grade, n (%) 0.247 Fisher
 0–2 279 (98.9) 141 (100) 138 (97.9)
 3–4 3 (1.1) 0 (0) 3 (2.1)
Platelet grade, n (%) 0.622 Fisher
 0–2 278 (98.6) 138 (97.9) 140 (99.3)
 3–4 4 (1.4) 3 (2.1) 1 (0.7)
Neutrophil grade, n (%) 0.275 1.194
 0–2 210 (74.5) 109 (77.3) 101 (71.6)
 3–4 72 (25.5) 32 (22.7) 40 (28.4)
Myelosuppression grade, n (%) 0.254 1.3
 0–2 189 (67.0) 99 (70.2) 90 (63.8)
 3–4 93 (33.0) 42 (29.8) 51 (36.2)

Bold indicates that the difference is statistically significant